Gamma-secretase modulator 3 is primarily investigated for its potential therapeutic applications in treating Alzheimer's disease. It works by modulating the activity of the gamma-secretase enzyme, which is involved in the production of amyloid-beta peptides. By altering the enzyme's function, it aims to reduce the formation of toxic amyloid-beta plaques, a hallmark of Alzheimer's pathology. This compound is part of ongoing research to develop targeted therapies that could slow or halt disease progression. Additionally, its mechanism of action is being explored for potential applications in other conditions linked to gamma-secretase dysregulation, such as certain cancers and developmental disorders.